Looks like you clickedhttps://cllsociety.org/2020/06/asco-2020-top-12-10-initial-results-of-a-multicenter-investigator-initiated-study-of-mrd-driven-time-limited-therapy-with-zanubrutinib-obinutuzumab-and-venetoclax/?utm_source=June+30%2C+2020&utm_campaign=June+30%2C+2020+Alert&utm_medium=email
If you do not want to visit that page, you can close this browser tab.
